In August 2021 the National Institute for Health Research (NIHR) notified us that their funding for our Cochrane Review Group, along with other groups in England, will cease at the end of March 2023. The Cochrane Cystic Fibrosis and Genetic Disorders Review Group have received many years of stable funding from the NIHR which has allowed our editorial base to support the production of systematic reviews and the sharing of knowledge to assess evidence contributing to these reviews. For this we are grateful; however, we are also saddened that the huge number of people who are part of our group across the world will lose the core editorial team who hold the group together and support the production of the Cochrane Reviews that are so important for patients, clinicians and decision-makers.
Cochrane is in the process of developing a new model of evidence synthesis, and you can join in that discussion here.
We are not certain what the future holds, but unfortunately there will not be a designated group of people employed to work on supporting and publishing Cochrane Reviews for cystic fibrosis, haemoglobinopathies, coagulopathies or inborn errors of metabolism after the end of March 2023. We are developing a plan to fulfil our obligations to the NIHR and also to produce the best reviews that we can for the public in the time we have left.
We will be working on producing a number of high-priority reviews and updates, and we will prioritise the completion of those that are already in development. We will contact lead authors of these reviews soon.
The Editorial Board have also decided that we will not register any new review titles to new author teams. Although we may make a small number of exceptions for author teams with a proven track record who propose to complete priority reviews, and who can demonstrate they have adequate support and a sensible timeline for delivery.